Overview

RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ryvu Therapeutics SA